# Qingyun Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qingyun-technology

- Industry: Marketing/Advertising
- Headquarters: Shanghai, China
- Website: www.socialmed.com.cn
- Total disclosed funding: $10M
- Latest round: Series C (Oct 8, 2022)
- Investors on record: 6

## About

Established in 2017 and based in Shanghai, China, Qingyun Technology is one of the first innovative technology companies in China to carry out virtual representation, focusing on artificial intelligence digital marketing in the pharmaceutical industry. The company's core team is from domestic CSO companies, and the total company platform has covered nearly 400,000 primary care doctors and cooperated with nearly 40 pharmaceutical companies, including Mercer, Merck, Pfizer, etc.

The company mainly provides multi-channel solutions for the digital marketing transformation of pharmaceutical companies, with virtual representatives as the core, artificial intelligence + big data analysis as the technical basis, and through the mutual promotion of medical groups and medical customer groups, constantly enriching marketing data, with business covering cardiovascular, respiratory, pain, anti-infection and vaccine and other medical fields.

The company raised a series C funding in October 2022, this round of funding will further accelerate the application upgrade and functional innovation of Eddie Qing's self-researched AI digital marketing platform.

## Funding rounds

- Series C, Oct 8, 2022, $10M — Long Hill Capital, Kangjun Capital
- Series B, Aug 27, 2021 — IDG Capital
- Series B, Jun 9, 2021 — Long Hill Capital, AliHealth, Lyzz Capital, Life Venture
- Series A, Jul 10, 2020 — Long Hill Capital

## Investors

- Long Hill Capital (https://capitalatlas.ai/funds/long-hill-capital) — Series A, Series B, Series C
- AliHealth — Series B
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B
- Life Venture — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series C